MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market MannKind (
NASDAQ:MNKD ) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into children and adolescents.
Chief Executive Officer Michael Castagna called the decision “a truly historic
What's Going On With MannKind Stock Friday? MannKind Corp. (
NASDAQ: MNKD ) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations.
Why MannKind Stock Tumbled on Thursday Mr. Market was hoping for a better fourth quarter than the company delivered.
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.”
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity.
Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop With shares battered and leverage rising, this quiet trim raises a sharper question about how much patience investors should have left.
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus investment case.
MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise MannKind (MNKD) Q3 2025 results beat revenue and EPS estimates. The biopharma's shares rose on strong performance and strategic updates, including the scPharmaceuticals acquisition.
